Recent Epidemiology of Nonalcoholic Fatty Liver Disease

키워드

참고문헌 (70)

1. Day CP, "Hepatic steatosis: innocent bystander or guilty party?", Hepatology, 27, pp.1463~1466 (1998)
2. Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
3. Caldwell SH, "Cryptogenic cirrhosis : clinical characterization and risk factors for underlying disease", Hepatology, 29, pp.664~669 (1999)
4. Ratziu V, "Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis", Hepatology, 35, pp.1485~1493 (2002)
5. Corey KE, "Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record", Dig Dis Sci, 61, pp.913~919 (2016)
6. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
7. Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
8. Whalley S, "Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs", Clin Med(Lond), 7, pp.119~124 (2007)
9. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
10. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
11. Allen AM, "Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death : a 20 year-community study", Hepatology, 67, pp.1726~1736 (2018)
12. Vernon G, "Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
13. Perumpail BJ, "Clinical epidemiology and disease burden of nonalcoholic fatty liver disease", World J Gastroenterol, 23, pp.8263~8276 (2017)
14. Muthiah MD, "Burden of disease due to nonalcoholic fatty liver disease", Gastroenterol Clin North Am, 49, pp.1~23 (2020)
15. Kim D, "Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States", Hepatology, 57, pp.1357~1365 (2013)
16. Abeysekera KWM, "Prevalence of steatosis and fibrosis in young adults in the UK : a population-based study", Lancet Gastroenterol Hepatol, 5, pp.295~305 (2020)
17. Younossi ZM, "Epidemiology of chronic liver diseases in the USA in the past three decades", Gut, 69, pp.564~568 (2020)
18. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
19. Kim D, "Race", ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016, 2019, pp.13, 205~213
20. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2diabetes : a systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
21. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
22. Kim D, "Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014", Liver Int, 39, pp.1661~1671 (2019)
23. Axley P, "NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States : a population-based study", Liver Transpl, 25, pp.695~705 (2019)
24. Allen AM, "Healthcare cost and utilization in nonalcoholic fatty liver disease : real-world data from a large U. S. claims database", Hepatology, 68, pp.2230~2238 (2018)
25. Yoo ER, "Economic burden and healthcare utilization in nonalcoholic fatty liver disease", Hepatobiliary Surg Nutr, 8, pp.181~183 (2019)
26. Hagström H, "Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls", Clin Gastroenterol Hepatol, 18, pp.1592~1599 (2020)
27. Andrew A. Li, "Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Gut and Liver, 14(2), pp.168~178 (2020), 거트앤리버 소화기연관학회협의회
28. Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
29. Berzigotti A, "Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis", Hepatology, 54, pp.555~561 (2011)
30. Kim D, "Nonobese fatty liver disease", Clin Gastroenterol Hepatol, 15, pp.474~485 (2017)
31. Kim D, "Non-overweight fatty liver disease(NOFLD) : a distinct entity", Hepatology, 56(S1), pp.886A~887A (2012)
32. Kim D, "Association between body sizemetabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis", J Gastroenterol, 55, pp.330~341 (2020)
33. Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
34. Kim D, "Increasing mortality among patients with diabetes and chronic liver disease from 2007 to 2017", Clin Gastroenterol Hepatol, 18, pp.992~994 (2020)
35. Tilg H, "NAFLD and diabetes mellitus", Nat Rev Gastroenterol Hepatol, 14, pp.32~42 (2017)
36. Anstee QM, "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis", Nat Rev Gastroenterol Hepatol, 10, pp.330~344 (2013)
37. Lazo M, "Prevalence of nonalcoholic fatty liver disease in the United States : the Third National Health and Nutrition Examination Survey, 1988-1994", Am J Epidemiol, 178, pp.38~45 (2013)
38. Golabi P, "Prevalence and outcomes of non-alcoholic fatty liver disease(NAFLD)among Asian American adults in the United States", Liver Int, 39, pp.748~757 (2019)
39. Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
40. Kwak MS, "Long-term outcomes of nonalcoholic fatty liver disease", Curr Hepatol Rep, 14, pp.69~76 (2015)
41. Alvarez CS, "Attributable fractions of NAFLD for mortality in the United States : results from NHANES III with 27 years of follow-up", Hepatology, 72, pp.430~440 (2020)
42. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
43. Siddiqui MS, "Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage", Clin Gastroenterol Hepatol, 17, pp.1877~1885 (2019)
44. Kim D, "Advanced fibrosis in nonalcoholic fatty liver disease : noninvasive assessment with MR elastography", Radiology, 268, pp.411~419 (2013)
45. Siddiqui MS, "Vibrationcontrolled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.156~163 (2019)
46. Loomba R, "Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis", Gastroenterology, 156, pp.88~95 (2019)
47. Jayakumar S, "Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis : analysis of data from a phase II trial of selonsertib", J Hepatol, 70, pp.133~141 (2019)
48. Sanyal A, "The natural history of advanced fibrosis due to nonalcoholic steatohepatitis : data from the simtuzumab trials", Hepatology, 70, pp.1913~1927 (2019)
49. Ajmera VH, "Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease", Hepatology, 71, pp.849~860 (2020)
50. Kleiner DE, "Association of histologic disease activity with progression of nonalcoholic fatty liver disease", JAMA Netw Open, 2, pp.e1912565~ (2019)
51. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and metaanalysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
52. Mandorfer M, "Impact of patatin-like phospholipase domain containing 3 rs738409G", G genotype on hepatic decompensation and mortality in patients with portal hypertension, 2018, pp.48, 451~459
53. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
54. Danford CJ, "A pathophysiologic approach combining genetics and insulin resistance to predict the severity of nonalcoholic fatty liver disease", Hepatol Commun, 2, pp.1467~1478 (2018)
55. Wijarnpreecha K, "PNPLA3gene polymorphism and overall and cardiovascular mortality in the United States", J Gastroenterol Hepatol, 35, pp.1789~1794 (2020)
56. Jayakumar S, "Review article : emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications", Aliment Pharmacol Ther, 50, pp.144~158 (2019)
57. Kim D, "Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016", Gastroenterology, 155, pp.1154~1163 (2018)
58. Kim D, "Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States", Hepatology, 69, pp.1064~1074 (2019)
59. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
60. Kim D, "Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017", Gastroenterology, 157, pp.1055~1066 (2019)
61. Younossi ZM, "In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not", Metabolism, 62, pp.352~360 (2013)
62. Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
63. Stepanova M, "Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population", Clin Gastroenterol Hepatol, 10, pp.646~650 (2012)
64. Vilar-Gomez E, "Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : a multi-national cohort study", Gastroenterology, 155, pp.443~457 (2018)
65. Targher G, "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease : a meta-analysis", J Hepatol, 65, pp.589~600 (2016)
66. Kim GA, "Association between nonalcoholic fatty liver disease and cancer incidence rate", J Hepatol, 68, pp.140~146 (2018)
67. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity : a longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
68. Cholankeril G, "Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States", Clin Gastroenterol Hepatol, 16, pp.1356~1358 (2018)
69. Younossi ZM, "Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to 2009", Hepatology, 62, pp.1723~1730 (2015)
70. Lazarus JV, "A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe", J Hepatol, 72, pp.14~24 (2020)

관련 논문AI추천